PP 33
Latest Information Update: 13 Aug 1998
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Phthalimides; Small molecules
- Mechanism of Action Tumour necrosis factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Aug 1998 Profile reviewed
- 13 Aug 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 17 Jul 1996 Preclinical development for Cancer in Japan (Unknown route)